Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Nudge Strategies to Increase the Adoption of DPYD Testing in Patients With Gastrointestinal (GI) Malignancies Treated With Fluoropyrimidines.

NCT06559462 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT06559462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06559462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Nudge Strategies to Increase the Adoption of DPYD Testing in Patients With Gastrointestinal (GI) Malignancies Treated With Fluoropyrimidines.
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Not applicable
Overall status
Completed
Start date
September 19, 2024
Completion date
August 28, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dpyd gene mutation, gastrointestinal cancer, health care seeking behavior